Evaluating systemic prednisone therapy for proliferating haemangioma in infancy

Jochen Rössler; Goetz Wehl; Charlotte Marie Niemeyer

doi:10.1007/s00431-007-0561-5

Evaluating systemic prednisone therapy for proliferating haemangioma in infancy

Eur J Pediatr. 2008 Jul;167(7):813-5. doi: 10.1007/s00431-007-0561-5. Epub 2007 Aug 4.

Authors

Jochen Rössler¹, Goetz Wehl, Charlotte Marie Niemeyer

Affiliation

¹ Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, University of Freiburg, Freiburg, Germany. jochen.roessler@uniklinik-freiburg.de

PMID: 17676341
DOI: 10.1007/s00431-007-0561-5

Abstract

In this study, we reviewed the history of 38 children with proliferating haemangiomas treated with systemic corticosteroids at our institution between 2000 and 2002. Prednisone was administered at an initial dose of 2 mg/kg per day for 2 weeks followed by a dose of 1 mg/kg per day for another 2-4 weeks and consecutive slow tapering over an additional 4-5 months. For 93% of the children, this protocol was successful in reducing the size of the haemangioma by more than 25% after 2 weeks of treatment. Side effects were moderate and reversible after cessation of therapy.

Publication types

Evaluation Study

MeSH terms

Adrenal Cortex Hormones / administration & dosage
Adrenal Cortex Hormones / adverse effects
Adrenal Cortex Hormones / therapeutic use*
Drug Administration Schedule
Female
Glucocorticoids / administration & dosage
Glucocorticoids / adverse effects
Glucocorticoids / therapeutic use*
Hemangioma / classification
Hemangioma / drug therapy*
Hemangioma / physiopathology
Humans
Infant
Male
Prednisone / administration & dosage
Prednisone / adverse effects
Prednisone / therapeutic use*
Retrospective Studies
Treatment Outcome

Substances

Adrenal Cortex Hormones
Glucocorticoids
Prednisone